BR9500732A - Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação - Google Patents

Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação

Info

Publication number
BR9500732A
BR9500732A BR9500732A BR9500732A BR9500732A BR 9500732 A BR9500732 A BR 9500732A BR 9500732 A BR9500732 A BR 9500732A BR 9500732 A BR9500732 A BR 9500732A BR 9500732 A BR9500732 A BR 9500732A
Authority
BR
Brazil
Prior art keywords
dna fragment
test kit
isolated dna
immunologically active
active peptide
Prior art date
Application number
BR9500732A
Other languages
English (en)
Other versions
BR9500732B8 (pt
BR9500732B1 (pt
Inventor
Stefan Dr Brust
Stefan Dr Knapp
Manfred Dr Gerken
Lutz G Prof Dr Guertler
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6510992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9500732(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of BR9500732A publication Critical patent/BR9500732A/pt
Publication of BR9500732B1 publication Critical patent/BR9500732B1/pt
Publication of BR9500732B8 publication Critical patent/BR9500732B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI9500732-6B8A 1994-02-23 1995-02-22 Kit diagnóstico para a detecção de anticorpos contra vírus que causam imunodeficiência. BR9500732B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4405810A DE4405810A1 (de) 1994-02-23 1994-02-23 Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung

Publications (3)

Publication Number Publication Date
BR9500732A true BR9500732A (pt) 1995-10-24
BR9500732B1 BR9500732B1 (pt) 2012-09-04
BR9500732B8 BR9500732B8 (pt) 2014-04-29

Family

ID=6510992

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9500732-6B8A BR9500732B8 (pt) 1994-02-23 1995-02-22 Kit diagnóstico para a detecção de anticorpos contra vírus que causam imunodeficiência.

Country Status (12)

Country Link
US (4) US5830634A (pt)
EP (1) EP0673948B1 (pt)
JP (1) JP2948121B2 (pt)
KR (1) KR100230880B1 (pt)
AT (1) ATE173275T1 (pt)
AU (1) AU697121B2 (pt)
BR (1) BR9500732B8 (pt)
CA (1) CA2143163C (pt)
DE (2) DE4405810A1 (pt)
DK (1) DK0673948T3 (pt)
ES (1) ES2124922T3 (pt)
NO (1) NO315163B1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
CA2222994A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Peptides for hiv-1 detection
US5977299A (en) * 1997-04-07 1999-11-02 Dade Behring Marburg Gmbh Activated peptides and conjugates
ES2275305T3 (es) 1997-04-09 2007-06-01 Bio-Rad Pasteur Peptidos sinteticos utilizables en los ensayos biologicos para la deteccion de infecciones debidas a los virus vih-1 del grupo o.
DE19718361A1 (de) 1997-05-02 1998-11-05 Dade Behring Marburg Gmbh Immunoassay zur Aviditätsbestimmung von Immunglobulinen
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2345399A (en) * 1998-01-28 1999-08-16 Universal Health-Watch, Inc. Divergent hiv-1 peptides
WO1999062945A2 (en) * 1998-06-05 1999-12-09 Peptide Solutions, Inc. Peptide antigens for detection of hiv, hcv and other microbial infections
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
WO2000042068A2 (en) * 1999-01-11 2000-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hiv related peptides
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2002314111A1 (en) * 2001-06-15 2003-01-02 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
US8043152B2 (en) * 2003-07-03 2011-10-25 Igt Methods and system for providing paper-based outcomes
DE602004028862D1 (de) * 2003-12-19 2010-10-07 Gen Probe Inc Der nukleinsäuren von hiv-1 und hiv-2
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
EP1851247A2 (en) 2005-02-15 2007-11-07 Thymon L.L.C. Methods and compositions for impairing multiplication of hiv-1
US20070122415A1 (en) * 2005-11-29 2007-05-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
US8438898B2 (en) * 2009-07-01 2013-05-14 Edwards Lifesciences Corporation Calibrant infusion fluid source preparation
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
RU2695653C2 (ru) 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN108997482A (zh) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328391B1 (en) 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
DE3588254T2 (de) * 1984-10-18 2008-06-26 Institut Pasteur GAG-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
CA1247082A (en) 1984-11-09 1988-12-20 Myron E. Essex Assay for detecting infection by human t-cell leukemia virus
EP0187041B1 (en) 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
US4774175A (en) 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IE64785B1 (en) 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
DK171119B1 (da) 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
ES2000859A6 (es) 1985-08-12 1988-03-16 Syntex Inc Un metodo para producir un vector de expresion bacteriana para la expresion de proteinas de fusion
US4803156A (en) 1985-09-11 1989-02-07 New York Blood Center Peptide-beta-lactamase conjugates for enzyme-linked immunoassays
GR862412B (en) 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
GB8525615D0 (en) 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides
DE3688051T2 (de) 1985-12-17 1993-06-24 Akzo Nv Immunochemisches reagenz.
US5079342A (en) 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
ATE47725T1 (de) 1986-01-22 1989-11-15 Pasteur Institut Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile.
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
WO1987007616A1 (en) 1986-06-12 1987-12-17 Biogen N.V. Peptides involved in the pathogenesis of hiv infection
US5034511A (en) 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
US5030714A (en) 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
EP0525828A3 (en) 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
AU606627B2 (en) 1986-11-01 1991-02-14 British Bio-Technology Limited Particulate hybrid hiv antigens
EP0269520A3 (fr) 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques
GB8629116D0 (en) 1986-12-05 1987-01-14 Hoffmann La Roche Env/gag polypeptides
JPS63258575A (ja) 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
US5030449A (en) 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
JPH0762031B2 (ja) 1986-12-30 1995-07-05 アメリカ合衆国 エイズウイルスおよびエイズウイルスのタンパク質に対する細胞性免疫を誘導する合成ペプチド
WO1988005440A1 (fr) 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
EP0300031A4 (en) 1987-01-28 1990-05-14 Ortho Pharma Corp IMMUNE SUPPRESSIVE PEPTIDES AND METHOD FOR THEIR USE.
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
NO881151L (no) 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
SE8701765L (sv) 1987-04-28 1988-10-29 Statens Bakteriologiska Lab Analysmetod och medel foer denna
AU620330B2 (en) 1987-05-29 1992-02-20 Smithkline Beckman Corporation Immunodiagnostic assays using chimeric antigens
GB8714802D0 (en) 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE3724016A1 (de) 1987-07-21 1989-02-02 Hans Prof Dr Dr Wolf Methoden fuer die gentechnologische produktion von antigenen sowie deren nutzung in einem neuen ansatz fuer bestaetigungsteste fuer antikoerper am beispiel des humanen immundefizienz-virus (hiv)
IL87391A0 (en) 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
DE3877294T2 (de) 1987-09-04 1993-05-06 Int Murex Tech Corp Festphasenimmunoassay fuer einen antikoerper und hierbei verwendete biologische produkte.
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US4863202A (en) * 1987-09-16 1989-09-05 Oldford William G Fluid connector assembly
EP0311228A3 (en) 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5019510A (en) * 1987-10-28 1991-05-28 Institut Pasteur Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor
ATE128716T1 (de) 1987-11-24 1995-10-15 Abbott Lab Hiv-peptide und methoden für den nachweis von hiv.
EP0323157A3 (en) 1987-12-24 1990-07-25 The University Of Melbourne Antiviral compounds and methods
JPH01179687A (ja) 1987-12-30 1989-07-17 Chemo Sero Therapeut Res Inst Ｈｉｖ融合蛋白質
IL89118A0 (en) 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
US5312737A (en) 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
US5124255A (en) 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
EP0408663A4 (en) 1988-04-07 1992-04-08 Univ Alabama Peptides inhibitors of hiv induced cell fusions and syncytia formation
AU3557889A (en) 1988-04-20 1989-11-24 Trustees Of The University Of Pennsylvania, The Protective peptides derived from human immunodeficiency virus-1 gp160
EP0339389B1 (de) 1988-04-25 1993-09-22 F. Hoffmann-La Roche Ag Diagnose-Hilfsmittel
JP2758900B2 (ja) 1988-05-16 1998-05-28 正憲 速水 ヒト免疫不全ウイルス２型の遺伝子ｒｎａに相補性を示すｄｎａ
EP0657532B1 (en) * 1988-06-09 2003-12-17 N.V. Innogenetics S.A. HIV-3 retrovirus strains and their use
EP0345792A3 (en) 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
EP0362909A3 (en) 1988-08-26 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies
DE68918867T2 (de) 1988-09-13 1995-02-16 Chiron Corp Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
JPH04502760A (ja) 1988-10-03 1992-05-21 レプリゲン・コーポレーション エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
GB8828098D0 (en) 1988-12-01 1989-01-05 Wellcome Found Peptides
US5223423A (en) 1989-03-31 1993-06-29 United States Of America Characterization of replication competent human immunodeficiency type 2 proviral clone hiv-2sbl/isy
FR2646606B1 (fr) 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
CA2025634A1 (en) 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
IE904083A1 (en) 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
DE4002636A1 (de) 1990-01-30 1991-08-01 Boehringer Mannheim Gmbh Expression von hiv1- und 2-polypeptiden und deren verwendung
CA2035576A1 (en) 1990-02-07 1991-08-08 Alexander R. Neurath Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1
ATE125157T1 (de) 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.
CA2078545A1 (en) 1990-04-03 1991-10-04 Timothy J. Gregory Hiv envelope polypeptides
US5013458A (en) 1990-04-06 1991-05-07 Rdp Company Process and apparatus for pathogen reduction in waste
WO1992000987A1 (en) 1990-07-12 1992-01-23 President And Fellows Of Harvard College Primate lentivirus vaccines
CA2050817A1 (en) 1990-09-24 1992-03-25 Emilio A. Emini Hiv-neutralizing rat monoclonal antibodies against pb-1
EP0550599B1 (en) 1990-09-27 2003-04-23 Tripep AB Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992006990A1 (en) 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof
FR2676071B1 (fr) 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
FR2677364A1 (fr) 1991-06-05 1992-12-11 Pasteur Institut Sequences peptidiques de la glycoproteine externe d'enveloppe du retrovirus hiv-1.
DE4318186C2 (de) 1993-06-01 2002-07-25 Dade Behring Marburg Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung

Also Published As

Publication number Publication date
US20050271678A1 (en) 2005-12-08
NO950668D0 (no) 1995-02-22
CA2143163A1 (en) 1995-08-24
JP2948121B2 (ja) 1999-09-13
BR9500732B8 (pt) 2014-04-29
US5830634A (en) 1998-11-03
ES2124922T3 (es) 1999-02-16
US20010009667A1 (en) 2001-07-26
EP0673948B1 (de) 1998-11-11
US20020123039A1 (en) 2002-09-05
AU1353295A (en) 1995-09-07
BR9500732B1 (pt) 2012-09-04
KR100230880B1 (ko) 1999-11-15
CA2143163C (en) 1999-12-28
EP0673948A1 (de) 1995-09-27
US6869608B2 (en) 2005-03-22
DE59504181D1 (de) 1998-12-17
NO950668L (no) 1995-08-24
DK0673948T3 (da) 1999-07-26
DE4405810A1 (de) 1995-08-24
ATE173275T1 (de) 1998-11-15
JPH07278189A (ja) 1995-10-24
AU697121B2 (en) 1998-09-24
KR950032278A (ko) 1995-12-20
NO315163B1 (no) 2003-07-21
US6335158B2 (en) 2002-01-01
US7803524B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
ES8801839A1 (es) Procedimiento para detectar anticuerpos a htlv-iii y diagnosticar aids, arc o estados pre-aids
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
KR900700469A (ko) 우레탄-보호된 아미노산-n-카르복시무수물
ES2191674T3 (es) Adrenomedulina.
FI932561A (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
ATE46703T1 (de) Regionspezifische determinanten fuer vitamin-k abhaengiges knochenprotein.
ES548421A0 (es) Un procedimiento para la obtencion de un anticuerpo monoclo-nal
KR870000356A (ko) 메티오닐 단백질로부터 n-말단 메티오닌을 제거하는 방법
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
DE69015708D1 (de) Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
NO900758D0 (no) Fremgangsmaate for fremstilling av hybridprotein.
DE69017352D1 (de) An HIV relatierte Peptide.
IT1241003B (it) Procedimento per la purificazione di un polipeptide ricombinante hdag equivalente, polipeptide hdag equivalente e saggi immunologici che lo utilizzano
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
ATE129504T1 (de) Allelische varianten von -i(plasmodium falciparum) merozoit-oberflächen-antigen.
ES8801958A1 (es) Un procedimiento para la determinacion de virus de sida
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
PC Transfer

Free format text: BEHRINGER DIAGNOSTICS GMBH. (DE)

TC Change of name
EG Technical examination (opinion): publication of technical examination (opinion)
HKEG Application refused (deleted)
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE)

Free format text: NOME ALTERADO DE: DADE BEHRING MARBURG GMBH

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/09/2012, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061597/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132275-84.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: RAQUALIA PHARMA INC., RESEARCH TRIANGLE PHAMACEUTICALS LTD., SHIONOGI AND CO., LTD. E SIEMSENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061597/2013 SECAO JUDICIARIA DO RIO DE JANEIRO-13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO0132275-84.2013.4.02.5101 AUTOR: INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL REU(S): RAQUALIA PHARMA INC.,RESEARCH TRIANGLE PHARMACEUTICALS LTD.,SHIONOGIAND CO.,LTD.E SIEMSENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH DECISAO: HOMOLOGO OS ACORDOS FIRMADOS, JULGANDO EXTINTO O PROCESSO COM RESOLUCAO DE MERITO, FORTE NO ART.269,III DO CODIGO DE PROCESSO CIVIL

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: CONFORME DETERMINACAO DO MM. JUIZ DA 13A VARA FEDERAL DO RIO DE JANEIRO, O PRAZO DE VIGENCIA DA PATENTE CONCEDIDA EM 04/09/2012 ATRAVES DA RPI 2174, E RETIFICADO PARA 22/02/2015.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/02/2015

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C07K 14/16; C07K 105/00; C07M 7/00; C12N 15/49; C12R 1/92; G01N 33/569; A61K 39/21.

Ipc: C07K 14/005 (2006.01), C07K 16/10 (2006.01), C12Q

Ipc: C07K 14/005 (2006.01), C07K 16/10 (2006.01), C12Q